

## Lytix Biopharma's licensing partner, Verrica Pharmaceuticals, to present data from VP-315 Phase II study at leading immuno-oncology conference SITC 2025

**Oslo, Norway, October 8, 2025** – Lytix Biopharma AS, a clinical-stage immuno-oncology company, is pleased to announce that its license partner Verrica Pharmaceuticals Inc. will present new data from its Phase II clinical trial of VP-315 (Ruxotemitide, formerly LTX-315) for the treatment of basal cell carcinoma (BCC) at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, taking place November 5–9, 2025 in National Harbor, Maryland, USA.

VP-315 will be featured in both an oral and a poster presentation during the conference. The abstract, titled “*Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)*”, (Abstract #529), will be presented as an oral presentation by Dr. Kenneth Tsai from the Moffitt Cancer Center on Friday, November 7. The abstract will be available on the SITC website on November 4, 2025.

The presentation will include exploratory analyses on local immune activation in the tumor microenvironment following VP-315 treatment. While the primary clinical outcomes from the Phase II study have previously been reported, this analysis provides additional insights into immune response activation in BCC patients.

“We are very pleased that Verrica’s trial with VP-315 has been selected for oral presentation at SITC, one of the most prominent global immuno-oncology conferences. “This recognition underscores the potential of Lytix’s technology platform and the progress we are making in advancing our unique oncolytic peptide approach.” said Øystein Rekdal, CEO of Lytix Biopharma.

VP-315 is licensed to Verrica Pharmaceuticals from Lytix Biopharma for certain dermatologic oncology indications, including basal cell carcinoma and cutaneous squamous cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. Lytix retains rights to all other cancer indications.

### **Abstract details:**

- Abstract Number: 529
- Title: Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)
- Presenting Author: Dr. Kenneth Tsai, Moffitt Cancer Center
- Presentation Type: Oral and Poster
- Presentation Day: Friday, November 7, 2025

### **For more information, please contact:**

Gjest Breistein, CFO

+47 952 60 512

[gjest.breistein@lytixbiopharma.com](mailto:gjest.breistein@lytixbiopharma.com)



**About Lytix:**

Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly novel technology based on world leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, Ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new principle to boost anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that can work in many different cancer indications and treatment settings, both as mono- and combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX.